{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-273340","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.046561+00:00","generated_at":"2026-05-16T22:26:32.125027+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"4DMT reports Q3 net loss $56.9M, enters Otsuka partnership for 4D-150 APAC rights for $85M upfront","bullets":["Net loss $56.9M in Q3 2025 vs $43.8M in Q3 2024; R&D expenses $49.4M (up from $38.5M).","Otsuka partnership: $85M upfront + $50M cost sharing; up to $336M milestones + royalties. 4DMT retains ex-APAC rights.","Cash $372M at Sept 30; + Otsuka payments + $93M equity raise extends runway into H2 2028.","4FRONT Phase 3 enrollment: >200 patients randomized in 4FRONT-1; topline data H1 2027. 4FRONT-2 on track.","Positive long-term PRISM (wet AMD) and SPECTRA (DME) data; 4D-150 well tolerated with durable benefit."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-273340","json":"https://secwatch.observer/filing/0001193125-25-273340.json","markdown":"https://secwatch.observer/filing/0001193125-25-273340.md","text":"https://secwatch.observer/filing/0001193125-25-273340.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312525273340/0001193125-25-273340-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312525273340/fdmt-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:26:32.125027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}